Amylin/IAPP (islet amyloid polypeptide) - Physiology and clinical relevance;Amylin/IAPP (Islet Amyloid Polypeptide) - Physiologie und klinische Bedeutung

Wiener Klinische Wochenschrift

Volumn 109, Issue 11, 1997, Pages 379-383

  Ludvik, Bernhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

diabetes mellitus; gastric emptying; insulin resistance; insulin secretion; pramlintide

Indexed keywords

AMYLIN; AMYLIN AGONIST; ANTIDIABETIC AGENT; PRAMLINTIDE; UNCLASSIFIED DRUG;

HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; REVIEW; STOMACH EMPTYING; SUBCUTANEOUS DRUG ADMINISTRATION;

AMYLOID; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC EMPTYING; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; PREGNANCY;

EID: 0030926058     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. DeFronzo R (1988) The triumvirate: B-cell, muscle and liver: a collusion responsible for NIDDM. Diabetes 37: 667-687
2. Opie EL (1901) On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to Diabetes mellitus. J Exp Med 5: 397-428
3. Weichselbaum A, Stangl E (1901) Zur Kenntnis der feineren Veränderungen des Pankreas bei Diabetes mellitus. Wien Klin Wochenschr 14: 968-972
4. Westermark P, Wernstedt C, Wilander E, Sletten K (1986) A novel peptide in the calcitonin gene related peptidc family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140: 826-831
5. Cooper GJS. Willis A, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of amyloidrich pancreases of type 2 diabetic patients, Proc Natl Acad Sci USA 84: 8628-8632
6. Cooper GJ, Leighton B, Dimitriades GD, Parry-Billings M, Kowalchuk JM, Howland K, et al (1988) Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 85: 7763-7766
7. Sowa R, Sanke T, Hirayama J, Tabata H, Furuta H, Nishimura S, et al (1990) Islet amyloid polypeptide causes peripheral insulin resistance in vivo in dogs. Diabetologia 33: 118-120
8. Oshawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S (1989) Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160: 961-967
9. Lukinius A, Wilander E, Westermark GT, Engström U, Westermark P (1989) Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32: 240-244
10. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E. et al (1991) Basal and stimulated plasma levels of amylin indicate its cosecretion with insulin in humans. Diabetologia 34: 52-54
11. Ludvik B, Leu B, Hartter E, Schnack C, Prager R (1991) Decrease of stimulated amylin precedes impairment of insulin secretion in type 2 diabetes. Diabetes 40: 1615-1619
12. Clark A, Cooper GJS, Lewis CE, Morris JF, Willis AC, Reid KBM. et al (1987) Islets amyloids formed from diabetes-associated peptide may be pathogenetic in type-2 diabetes. Lancet: 231-234
13. Cooper GJS (1994) Amyhn compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocrine Reviews 15: 163-201
14. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia J, Kreutter DK, et al (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Diabetes 45 [Suppl] 2: 159A
15. Soeller WC, Parker JC, Janson J, Nelson RT, Carty MD, Torchia AJ, et al (1996) Two distinct diabetogenic roles for IAPP and rodent homologues in transgenic mice. Diabetes 45 [Suppl] 2: 161A
16. Lorenzo A, Razzaboni B, Weir GC, Yankner BA (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368: 756-760
17. Castillo MJ, Scheen AJ, Lefebvre PJ (1995) Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete & Metabolisme 21: 3-25
18. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, et al (1995) A non invasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 95: 2232-2238
19. Ludvik B, Clodi M, Kautzky-Willer A, Schuller M, Graf H, Hartter E, et al (1994) Increased levels of circulating islet amyloid polypeptidc in patients with chronic renal failure have no effect on insulin secretion. J Clin Invest 94: 2045-2050
20. Kautzky-Willer A, Tomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, et al (1994) Role of islet amyloid polypeptide secretion in insulin resistant humans. Diabetologia 37: 188-194
21. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G (1996) An integrated mathematical model to assess B-cell activity during the oral glucose test. Am J Physiol 270 (Endocrinol Metab 33): E522-E531
22. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, et al (1993) Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptidc and insulin secretion in humans. Diabetologia 36: 84-87
23. Kautzky-Willer A, Ludvik~B, Thomaseth K, Pacini G, Prager R (1996) Elevated IAPP secretion and proinsulin levels in gestational diabetes. Diabetes 45 [Suppl] 2: 180A
24. Permert J, Larsson J, Westermark GT, Jerrington MK, Christmanson L, Pour PM. et al (1994) Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 330: 313-318
25. Blackard WG, Clore JN, Kellmun JM (1994) Amylin/ insulin secretory ratios in morbidity obese man. inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 78: 1257-1260
26. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai M, Nishirnura S, et al (1991) Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 129-132
27. Ludvik B, Nolan JJ, Thomaseth K, Pacini G, Clodi M, Prager R, et al (1996) Direct assessment of secretion, kinetics and clearance of B-cell peptides during hepatic vein catheterization. Diabetes 45 [Suppl] 2: 165A
28. Hulst KLV, Nicuwenhuis MG, Höppener JWM, Lips CJM, Blankenstein MA (1996) Lack of islet amyloid polypeptide/amylin-immunoreactivity in urine collected from healthy volunteers after ingestion of a carbohydrate-rich meal. Exp Clin Endocrinol 104: 177-179
29. Young AA, Wang MW, Cooper GJS (1991) Amylin injection causes elevated plasma lactatc and glucose in the rat. FEES Lett 291: 101-104
30. Molina JM, Cooper GJS, Leighton B, Olefsky JM (1990) Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 39: 260-265
31. Wildling JPH, Khandan-Nia N, Bennet WM, Glibey SJ, Beacham J, Ghatei MA. et al (1994) Lack of acute effects of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinemic euglycemic clamp in humans. Diabetologia 37: 166-169
32. Silvestre RA, Peiro E, Degano P, Miralles P, Marco J (1990) Inhibitors effect of rat amylin on the insulin response to glucose and arginine in the perfused rat pancreas. Regulatory Peptides 31: 23-31
33. O'Brien TD, Westermark P, Johnson KH (1990) Islet amyloid polypeptide (IAPP) does not inhibit glucose-stimulated insulin secretion from isolates perfused rat pancreas. Biochem Biophys Res Commun 170: 1223-1228
34. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Macrae AD, Bloom SR (1992) Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 74: 1032-1035
35. Leaming R, Johnson A, Hook G, Hanley R, Baron A (1995) Amylin modulates insulin secretion in humans. Studies with an amylin antagonist. Diabetologia 38 [Suppl] 1: A113: 437
36. Young AA, Jodka CM, Green DE, Gedulin BR (1994) Inhibition of arginine-induced glucagon secretion by amylin in rats. Diabetes 44: 238A
37. Nyholm B, Moller N, Gravholt CH, Orskov L, Mengel A, Bryan G, et al (1996) Acute effects of the human amylin analog AC 137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81: 1083-1089
38. Kolterman OG, Schwantz S, Corder C, Levy B, Klaff L, Peterson J. et al (1996) Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC 137). on an intravenous insulin challenge and response to a standard lipid meal in patients with IDDM. Diabetologia 39: 492-499
39. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA (1984) Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic glucose uptake and effect of intensive insulin therapy. J Clin Invest 74: 985-991
40. MacIntyre I (1989) Amylinamide, bone conservation, and pancreatic B-cells. Lancet ii: 1026-1027
41. Chance WT, Balasubmarmaniam A, Zhang FS, Wimalawansa SJ, Fischer JE (1991) Anorexia following the intrahypothalamic administration of amylin. Brain Res 539: 352-354